Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri System
    • Missouri Summits
    • Missouri Regional Life Sciences Summit 2010
    • Abstracts (Missouri Regional Life Sciences Summit 2010)
    • View Item
    •   MOspace Home
    • University of Missouri System
    • Missouri Summits
    • Missouri Regional Life Sciences Summit 2010
    • Abstracts (Missouri Regional Life Sciences Summit 2010)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    Impact of Clopidogrel Pretreatment on Ischemic Complications of PCI among Bivalirudin-Treated Patients: Results from the EVENT Registry

    Amin, Amit P.
    Kennedy, Kevin
    Pencina, Michael
    Berger, Peter
    Piana, Robert N.
    Lopez, John
    Kleiman, Neal
    Cohen, David J.
    View/Open
    [PDF] ImpactClopidogrelPretreatment[abstract].pdf (80.03Kb)
    [PDF] ImpactClopidogrelPretreatment.pdf (592.4Kb)
    Date
    2010-03
    Contributor
    University of Missouri (System)
    Format
    Poster
    Metadata
    [+] Show full item record
    Abstract
    Background: Although clopidogrel (CLO) pretreatment benefits PCI patients with acute coronary syndromes, these benefits are less well-established among elective PCI patients—particularly when treated with the direct thrombin inhibitor (DTI), bivalirudin. The effect of timing of CLO pretreatment on ischemic complications in these patients is also unknown. Methods: We used data from the multicenter EVENT registry to assess the association of clopidogrel pretreatment (600 mg 2 hr pre-PCI, 300 mg 6 hrs pre-PCI, or 75 mg/d for 1 week) with PCI-related complications in patients undergoing elective PCI with a DTI as planned antithrombotic. The primary endpoint was the composite of in-hospital death or MI (peak CKMB > 3 x ULN). Results: Between 01/05 and 12/07, 3568 pts underwent elective PCI and 1913 (54%) received DTI as planned anticoagulant (37% diabetics, age 65±10 y). Clopidogrel pre-treatment was used in 923 (48%). There were no differences in in-hospital or 1 year ischemic or bleeding events in relation to clopidogrel pretreatment in both unadjusted and adjusted analyses (see Table). There was a trend toward lower rates of death or MI with earlier pretreatment, however [Odds ratios vs. no pretreatment: >1 week 0.48 (95% CI 0.08 - 2.73); > 6 h OR 0.69 (95% CI 0.11 - 4.45) and 2-6 h OR 0.77 (95% CI 0.18 - 3.31)]. Conclusion: Among unselected patients undergoing elective PCI with DTI as the planned anticoagulant, clopidogrel pretreatment was common, but was not associated with a reduced risk of ischemic complications.
    URI
    http://hdl.handle.net/10355/6223
    Part of
    Abstracts (Missouri Regional Life Sciences Summit 2010)
    Collections
    • Posters (Missouri Regional Life Sciences Summit 2010)
    • Abstracts (Missouri Regional Life Sciences Summit 2010)

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems